Lyophilized Injectable Drugs Global Market Report 2024

The lyophilized injectable drugs market size has grown steadily in recent years. It will grow from $3.82 billion in 2023 to $3.93 billion in 2024 at a compound annual growth rate (CAGR) of 3.0%. The growth observed in the historical period can be attributed to several key factors, including the rise in chronic diseases, the expansion of the biopharmaceutical industry, an increasing geriatric population, advancements in clinical practices and trials, and the globalization of pharmaceutical manufacturing. These factors collectively contributed to the growth and development of the healthcare and pharmaceutical sectors during the specified historic period.

The lyophilized injectable drugs market size is expected to see steady growth in the next few years. It will grow to $4.48 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The projected growth during the forecast period is driven by the increasing adoption of personalized medicine, the expansion of the biologics pipeline, global health readiness efforts, heightened demand for orphan drugs, and a growing emphasis on patient compliance. Noteworthy trends anticipated in the forecast period encompass innovations in lyophilized combination therapies, the extension of lyophilized vaccines, the incorporation of quality-by-design (QbD) principles, the application of lyophilized drugs in emergency medicine, and regulatory focus on the validation of lyophilization processes.

The anticipated surge in the lyophilized injectable drugs market is attributed to the increasing prevalence of cardiac disorders. Cardiac disorders encompass a diverse range of conditions affecting the heart's structure and function, including valves, chambers, blood arteries, the electrical system, and overall pumping function. Lyophilized injectable drugs, such as thrombolytic agents, antiarrhythmic medications, inotropic agents, and antihypertensive medications, play a crucial role in treating various cardiac disorders. Their usage is driven by factors such as stability, convenience, flexibility, rapid reconstitution, improved bioavailability, and a reduced risk of contamination.

The growth of the lyophilized injectable drugs market is further propelled by the global rise in cardiac disorders. For example, a report from the Centers for Disease Control and Prevention (CDC) in May 2023 highlighted that coronary heart disease claimed the lives of 375,476 individuals in 2021. Additionally, data from the New York government in December 2022 revealed that heart disease results in approximately 697,000 deaths annually in the United States. Of these, 805,000 Americans experience a heart attack each year, with 605,000 being first-time occurrences and 200,000 resulting from previous heart attacks. Consequently, the increasing incidence of cardiac disorders is a key driver for the growth of the lyophilized injectable drugs market during the forecast period.

The escalating incidence of cardiovascular diseases is poised to propel the lyophilized injectable drugs market. Cardiovascular diseases encompass a spectrum of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and heart valve problems. Lyophilized injectable drugs address cardiovascular diseases by providing stable and durable formulations that enhance drug efficacy, ensure precise dosing, and enable convenient administration. This contributes to improved patient outcomes and treatment compliance. In 2022, according to data from the Centers for Disease Control and Prevention (CDC), heart disease accounted for over 659,000 deaths in the United States, representing one in every four fatalities. Specifically, coronary heart disease, the most prevalent type, claimed 375,476 lives in 2021. Therefore, the escalating cases of cardiovascular diseases are expected to drive the lyophilized injectable drugs market forward.

The prevailing trend in the lyophilized injectable drug market is the emphasis on product innovations, with major companies actively pursuing novel drug delivery systems to enhance their market profitability. Notably, in June 2022, Gufic Biosciences Ltd., an India-based pharmaceutical company, introduced Dual Chamber Bags (DCB), a critical innovation for reconstituting lyophilized injectable drugs. These bags offer multiple advantages, including a reduction in the risk of bloodstream infections, ensuring patient safety, and preventing prescription errors.

Leading companies in the lyophilized injectable drug market are channeling their efforts into leveraging innovative technologies, such as non-invasive technology, for the development of lyophilized injectable drugs. Non-invasive technology involves methods or devices that gather information or perform tasks without penetrating the skin or entering bodily orifices. For example, in October 2023, COMSER Pharma, a Spain-based provider of compliance services and freeze-dry pharmaceutical solutions, introduced LyoFlow, an innovative technology for lyophilized injectable drug production. LyoFlow is a disruptive solution enabling real-time, non-invasive extraction of the mass flow in a freeze-drying process, easily integratable into any lyophilization equipment, and facilitating continuous monitoring of product quality throughout the process.

In April 2022, Recipharm AB, a pharmaceutical contract development and manufacturing organization based in Sweden, acquired Vibalogics for an undisclosed amount. This acquisition aims to reinforce the company's position in the biologics market, with a specific focus on manufacturing drug ingredients for novel advanced therapeutic medicinal goods. Vibalogics, a Germany-based manufacturing company, specializes in the production of sophisticated live biological products, operating within the lyophilized injectable drugs market.

Major companies operating in the lyophilized injectable drugs market report are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co Inc., Sanofi SA, Novo Nordisk A/S, Becton Dickinson and Company, Baxter International Inc., Sandoz, Nipro Corporation, B. Braun SE, Aurobindo Pharmaceuticals, Schott AG, Zydus Lifesciences, Recipharm AB, Vetter Pharma-Fertigung GmbH & Co. KG, Fresenius Kabi USA LLC, Vetter Pharma-Fertigung GmbH & Co. KG, CordenPharma International, Aristopharma Limited., Accord Healthcare, Jubilant HollisterStier LLC, Ciron Drugs & Pharmaceuticals Pvt Ltd., MSN Laboratories, Qilu pharmaceutical Co Ltd., Genex Pharma. North America was the largest region in the lyophilized injectable drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyophilized injectable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

These drugs are packaged in various types, including specialty packaging, point-of-care reconstitution, single-use vials, and others. Point-of-care reconstitution involves preparing medication for immediate use by reconstituting a lyophilized drug at the point of administration or patient bedside. Different delivery methods include single-step devices, multi-step devices, prefilled diluent syringes, and proprietary reconstitution devices. These devices are utilized in the treatment of various conditions such as infectious diseases, autoimmune diseases, and metabolic conditions. The end-users of lyophilized injectable drugs encompass hospitals, ambulatory surgery centers (ASCs), specialty clinics, and other healthcare facilities.

The lyophilized injectable drugs market research report is one of a series of new reports that provides lyophilized injectable drugs market statistics, including lyophilized injectable drugs industry global market size, regional shares, competitors with a lyophilized injectable drugs market share, detailed lyophilized injectable drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the lyophilized injectable drugs industry. This lyophilized injectable drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the lyophilized injectable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lyophilized injectable drugs market consists of revenue by entities by providing Pre-freezing, primary drying, and secondary drying. The market value includes the value of related goods sold by the service provider or included within the service offering. The lyophilized injectable drugs market also includes sales of ceftriaxone, vancomycin, and meropenem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.